heart failure
Conditions
Interventions
Stage A (at-risk for heart failure) group:Standard heart failure therapy (diuresis vasodilatation improvement of heart function etc.)
Stage B (Pre-heart failure) group:Standard heart failure therapy (diuresis vasodilatation improvement of heart function etc.)
Stage C (heart failure) group:Standard heart failure therapy (diuresis vasodilatation improvement of heart function etc.)
Stage D (end-stage heart failure) group:Standard heart failure therapy (diuresis vasodilatation improvement of heart function etc.)
Sponsors
Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Meet the diagnostic criteria of heart failure and new staging; aged 18 years or above; voluntarily enrolled in this trial signed the informed consent form had good compliance and could cooperate in receiving follow-up visits by telephone and other forms;
Exclusion criteria
Exclusion criteria: Patients with end-stage tumors liver and kidney failure; those with acute stages of infection that may interfere with the diagnostic accuracy of the program; and patients with comorbid psychiatric conditions;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-month composite major adverse cardiovascular events (MACE); | — |
Secondary
| Measure | Time frame |
|---|---|
| Chinese Medicine Score;ACC/AHA HF stage A–D;Left-ventricular ejection fraction (LVEF);Baseline NT-proBNP;Urine output;Liver function (ALT, AST, TBil);Renal function (Scr, eGFR);HF-related rehospitalisations;Correlation between dampness score & HF stage;Predictive model AUC;Change in NT-proBNP; | — |
Countries
China
Contacts
Public ContactYun-hu Chen
Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine
Outcome results
None listed